Results 31 to 40 of about 7,431,159 (264)

Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug-gene interactions. [PDF]

Front Pharmacol
Palbociclib, an oral inhibitor of cyclin-dependent kinase 4 and 6, is approved for the treatment of metastatic breast cancer. This study investigated the influence of diverse clinical and biological factors—age, renal function, genetic variations, and ...
Peruzzi E, Posocco B, Gerratana L, Nuti M, Orleni M, Gagno S, De Mattia E, Puglisi F, Cecchin E, Toffoli G, Roncato R.   +10 more
europepmc   +2 more sources

ACE2 Netlas: In silico Functional Characterization and Drug-Gene Interactions of ACE2 Gene Network to Understand Its Potential Involvement in COVID-19 Susceptibility. [PDF]

Front Genet, 2021
Angiotensin-converting enzyme-2 (ACE2) receptor has been identified as the key adhesion molecule for the transmission of the SARS-CoV-2. However, there is no evidence that human genetic variation in ACE2 is singularly responsible for COVID-19 ...
Pathak GA, Wendt FR, Goswami A, Koller D, De Angelis F, COVID-19 Host Genetics Initiative, Polimanti R.   +6 more
europepmc   +2 more sources

Drug‐Drug‐Gene Interactions: A Call for Clinical Consideration [PDF]

Clinical pharmacology and therapy, 2021
It is widely accepted that both comedications and genetic factors may contribute to variation of drug response. Clinical decision support systems increasingly consider recommendations on drug– drug interactions (DDIs) during electronic prescribing, and ...
Henrike Bruckmueller, I. Cascorbi
semanticscholar   +3 more sources

Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. [PDF]

Pharmaceutics, 2020
The beta-blocker metoprolol (the sixth most commonly prescribed drug in the USA in 2017) is subject to considerable drug–gene interaction (DGI) effects caused by genetic variations of the CYP2D6 gene. CYP2D6 poor metabolizers (5.7% of US population) show
Rüdesheim S, Wojtyniak JG, Selzer D, Hanke N, Mahfoud F, Schwab M, Lehr T.   +6 more
europepmc   +2 more sources

Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study. [PDF]

BMC Med, 2020
Background The number of patients living with co-existing diseases is growing. This study aimed to assess the extent of multimorbidity, medication use, and drug- and gene-based interactions in patients following a non-ST elevation acute coronary syndrome
Turner RM, de Koning EM, Fontana V, Thompson A, Pirmohamed M.   +4 more
europepmc   +2 more sources

Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole. [PDF]

Clin Pharmacokinet, 2019
BackgroundDrug–drug interactions (DDIs) and drug–gene interactions (DGIs) pose a serious health risk that can be avoided by dose adaptation. These interactions are investigated in strictly controlled setups, quantifying the effect of one perpetrator drug
Türk D, Hanke N, Wolf S, Frechen S, Eissing T, Wendl T, Schwab M, Lehr T.   +7 more
europepmc   +2 more sources

Optimising Seniors' Metabolism of Medications and Avoiding Adverse Drug Events Using Data on How Metabolism by Their P450 Enzymes Varies with Ancestry and Drug-Drug and Drug-Drug-Gene Interactions. [PDF]

J Pers Med, 2020
Many individuals ≥65 have multiple illnesses and polypharmacy. Primary care physicians prescribe >70% of their medications and renew specialists’ prescriptions. Seventy-five percent of all medications are metabolised by P450 cytochrome enzymes.
Thomas RE.
europepmc   +2 more sources

Machine learning workflow to enhance predictions of Adverse Drug Reactions (ADRs) through drug-gene interactions: application to drugs for cutaneous diseases. [PDF]

Sci Rep, 2017
Adverse drug reactions (ADRs) pose critical public health issues, affecting over 6% of hospitalized patients. While knowledge of potential drug-drug interactions (DDI) is necessary to prevent ADR, the rapid pace of drug discovery makes it challenging to ...
Raja K, Patrick M, Elder JT, Tsoi LC.
europepmc   +2 more sources

Understanding and preventing drug-drug and drug-gene interactions. [PDF]

Expert Rev Clin Pharmacol, 2014
Concomitant administration of multiple drugs can lead to unanticipated drug interactions and resultant adverse drug events with their associated costs.
Tannenbaum C, Sheehan NL.
europepmc   +2 more sources

Population-Based Assessment of Phenoconversion Potential in Switzerland: A Claims Data Study of Key Drug-Metabolizing Enzymes and Transporters [PDF]

Pharmacogenomics and Personalized Medicine
Marietta M Roth,1,2,* Aline Bencastro,1,2,* Christoph R Meier,1,2 Carola A Huber,3 Henriette E Meyer zu Schwabedissen,4 Samuel S Allemann,5,* Cornelia Schneider1,2,* 1Basel Pharmacoepidemiology Unit, Division of Clinical ...
Roth MM, Bencastro A, Meier CR, Huber CA, Meyer zu Schwabedissen HE, Allemann SS, Schneider C   +6 more
doaj   +2 more sources